Skip to main content
Top
Published in: Journal of Translational Medicine 1/2022

Open Access 01-12-2022 | Ovarian Cancer | Research

Acidic ascites inhibits ovarian cancer cell proliferation and correlates with the metabolomic, lipidomic and inflammatory phenotype of human patients

Authors: Qianlu Yang, Gyuntae Bae, Giorgi Nadiradze, Arianna Castagna, Georgy Berezhnoy, Laimdota Zizmare, Aditi Kulkarni, Yogesh Singh, Frank J. Weinreich, Stefan Kommoss, Marc A. Reymond, Christoph Trautwein

Published in: Journal of Translational Medicine | Issue 1/2022

Login to get access

Abstract

Background

The poor prognosis of ovarian cancer patients is strongly related to peritoneal metastasis with the production of malignant ascites. However, it remains largely unclear how ascites in the peritoneal cavity influences tumor metabolism and recurrence. This study is an explorative approach aimed at for a deeper molecular and physical–chemical characterization of malignant ascites and to investigate their effect on in vitro ovarian cancer cell proliferation.

Methods

This study included 10 malignant ascites specimens from patients undergoing ovarian cancer resection. Ascites samples were deeply phenotyped by 1H-NMR based metabolomics, blood-gas analyzer based gas flow analysis and flow cytomertry based a 13-plex cytokine panel. Characteristics of tumor cells were investigated in a 3D spheroid model by SEM and metabolic activity, adhesion, anti-apoptosis, migratory ability evaluated by MTT assay, adhesion assay, flowcytometry and scratch assay. The effect of different pH values was assessed by adding 10% malignant ascites to the test samples.

Results

 The overall extracellular (peritoneal) environment was alkaline, with pH of ascites at stage II-III = 7.51 ± 0.16, and stage IV = 7.78 ± 0.16. Ovarian cancer spheroids grew rapidly in a slightly alkaline environment. Decreasing pH of the cell culture medium suppressed tumor features, metabolic activity, adhesion, anti-apoptosis, and migratory ability. However, 10% ascites could prevent tumor cells from being affected by acidic pH. Metabolomics analysis identified stage IV patients had significantly higher concentrations of alanine, isoleucine, phenylalanine, and glutamine than stage II-III patients, while stage II-III patients had significantly higher concentrations of 3-hydroxybutyrate. pH was positively correlated with acetate, and acetate positively correlated with lipid compounds. IL-8 was positively correlated with lipid metabolites and acetate. Glutathione and carnitine were negatively correlated with cytokines IL-6 and chemokines (IL-8 & MCP-1).

Conclusion

Alkaline malignant ascites facilitated ovarian cancer progression. Additionally, deep ascites phenotyping by metabolomics and cytokine investigations allows for a refined stratification of ovarian cancer patients. These findings contribute to the understanding of ascites pathology in ovarian cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Momenimovahed Z, et al. Ovarian cancer in the world: epidemiology and risk factors. Int J Women’s Health. 2019;11:287.CrossRef Momenimovahed Z, et al. Ovarian cancer in the world: epidemiology and risk factors. Int J Women’s Health. 2019;11:287.CrossRef
2.
go back to reference Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Can Res. 2010;70(14):5649–69.CrossRef Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Can Res. 2010;70(14):5649–69.CrossRef
3.
go back to reference Sluiter N, et al. Adhesion molecules in peritoneal dissemination: function, prognostic relevance and therapeutic options. Clin Exp Metas. 2016;33(5):401–16.CrossRef Sluiter N, et al. Adhesion molecules in peritoneal dissemination: function, prognostic relevance and therapeutic options. Clin Exp Metas. 2016;33(5):401–16.CrossRef
4.
go back to reference Archid R, Solass W, Tempfer C, Königsrainer A, Adolph M, Reymond MA, Wilson RB. Cachexia anorexia syndrome and associated metabolic dysfunction in peritoneal metastasis. Int J Mol Sci. 2019;20(21):5444.CrossRef Archid R, Solass W, Tempfer C, Königsrainer A, Adolph M, Reymond MA, Wilson RB. Cachexia anorexia syndrome and associated metabolic dysfunction in peritoneal metastasis. Int J Mol Sci. 2019;20(21):5444.CrossRef
5.
go back to reference Hilal Z, et al. Nutritional status, cachexia, and anorexia in women with peritoneal metastasis and intraperitoneal chemotherapy: a longitudinal analysis. J Gynecol Oncol. 2017;28(6): e80.CrossRef Hilal Z, et al. Nutritional status, cachexia, and anorexia in women with peritoneal metastasis and intraperitoneal chemotherapy: a longitudinal analysis. J Gynecol Oncol. 2017;28(6): e80.CrossRef
6.
go back to reference Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013;13(4):273–82.CrossRef Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013;13(4):273–82.CrossRef
7.
go back to reference Thibault B, et al. Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition. Cancer Metastasis Rev. 2014;33(1):17–39.CrossRef Thibault B, et al. Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition. Cancer Metastasis Rev. 2014;33(1):17–39.CrossRef
8.
go back to reference Chen F, et al. New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med. 2015;13(1):1–14.CrossRef Chen F, et al. New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med. 2015;13(1):1–14.CrossRef
9.
go back to reference Webb BA, et al. Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer. 2011;11(9):671–7.CrossRef Webb BA, et al. Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer. 2011;11(9):671–7.CrossRef
10.
go back to reference Roy S, et al. Hypoxic tumor microenvironment: implications for cancer therapy. Exp Biol Med. 2020;245(13):1073–86.CrossRef Roy S, et al. Hypoxic tumor microenvironment: implications for cancer therapy. Exp Biol Med. 2020;245(13):1073–86.CrossRef
11.
go back to reference Hanash SM, Pitteri SJ, Faca VMJN. Mining the plasma proteome for cancer biomarkers. Nature. 2008;452(7187):571–9.CrossRef Hanash SM, Pitteri SJ, Faca VMJN. Mining the plasma proteome for cancer biomarkers. Nature. 2008;452(7187):571–9.CrossRef
12.
go back to reference Buchheit CL, Weigel KJ, Schafer ZT. Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression. Nat Rev Cancer. 2014;14(9):632–41.CrossRef Buchheit CL, Weigel KJ, Schafer ZT. Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression. Nat Rev Cancer. 2014;14(9):632–41.CrossRef
13.
go back to reference Simpson CD, Anyiwe K, Schimmer AD. Anoikis resistance and tumor metastasis. Cancer Lett. 2008;272(2):177–85.CrossRef Simpson CD, Anyiwe K, Schimmer AD. Anoikis resistance and tumor metastasis. Cancer Lett. 2008;272(2):177–85.CrossRef
14.
go back to reference Hawk MA, Schafer ZT. Mechanisms of redox metabolism and cancer cell survival during extracellular matrix detachment. J Biol Chem. 2018;293(20):7531–7.CrossRef Hawk MA, Schafer ZT. Mechanisms of redox metabolism and cancer cell survival during extracellular matrix detachment. J Biol Chem. 2018;293(20):7531–7.CrossRef
15.
go back to reference Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8(6):519–30.CrossRef Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8(6):519–30.CrossRef
16.
go back to reference Gao Q, et al. Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer. J Exp Med. 2019;216(3):688–703.CrossRef Gao Q, et al. Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer. J Exp Med. 2019;216(3):688–703.CrossRef
17.
go back to reference Gao Q, et al. Heterotypic CAF-tumor spheroids promote early peritoneal metastasis of ovarian cancer. J Exp Med. 2019;216(3):688–703.CrossRef Gao Q, et al. Heterotypic CAF-tumor spheroids promote early peritoneal metastasis of ovarian cancer. J Exp Med. 2019;216(3):688–703.CrossRef
18.
go back to reference Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005;102(43):15545–50.CrossRef Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005;102(43):15545–50.CrossRef
19.
go back to reference Putnam TJ. The living peritoneum as a dialyzing membrane. AJP-Legacy. 1923;63(3):548–65. Putnam TJ. The living peritoneum as a dialyzing membrane. AJP-Legacy. 1923;63(3):548–65.
20.
go back to reference Cavazzoni E, et al. Malignant ascites: pathophysiology and treatment. Int J Clin Oncol. 2013;18(1):1–9.CrossRef Cavazzoni E, et al. Malignant ascites: pathophysiology and treatment. Int J Clin Oncol. 2013;18(1):1–9.CrossRef
21.
go back to reference Yigit R, et al. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol. 2010;117(2):366–72.CrossRef Yigit R, et al. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol. 2010;117(2):366–72.CrossRef
22.
go back to reference Uruski P, et al. Malignant ascites promote adhesion of ovarian cancer cells to peritoneal mesothelium and fibroblasts. Int J Mol Sci. 2021;22(8):4222.CrossRef Uruski P, et al. Malignant ascites promote adhesion of ovarian cancer cells to peritoneal mesothelium and fibroblasts. Int J Mol Sci. 2021;22(8):4222.CrossRef
23.
go back to reference Pakuła M, et al. The epithelial-mesenchymal transition initiated by malignant ascites underlies the transmesothelial invasion of ovarian cancer cells. Int J Mol Sci. 2019;20(1):137.CrossRef Pakuła M, et al. The epithelial-mesenchymal transition initiated by malignant ascites underlies the transmesothelial invasion of ovarian cancer cells. Int J Mol Sci. 2019;20(1):137.CrossRef
24.
go back to reference Mürdter TE, et al. Dose optimization of a doxorubicin prodrug (HMR 1826) in isolated perfused human lungs: low tumor pH promotes prodrug activation by β-glucuronidase. J Pharmacol Exp Ther. 2002;301(1):223–8.CrossRef Mürdter TE, et al. Dose optimization of a doxorubicin prodrug (HMR 1826) in isolated perfused human lungs: low tumor pH promotes prodrug activation by β-glucuronidase. J Pharmacol Exp Ther. 2002;301(1):223–8.CrossRef
25.
go back to reference Laks H, Dmochowski JR, Couch NP. The relationship between muscle surface pH and oxygen transport. Ann Surg. 1976;183(2):193.CrossRef Laks H, Dmochowski JR, Couch NP. The relationship between muscle surface pH and oxygen transport. Ann Surg. 1976;183(2):193.CrossRef
26.
go back to reference Chen RR, et al. Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells. Commun Biol. 2019;2(1):1–15.CrossRef Chen RR, et al. Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells. Commun Biol. 2019;2(1):1–15.CrossRef
27.
go back to reference Liu X, et al. Acetate production from glucose and coupling to mitochondrial metabolism in mammals. Cell. 2018;175(2):502-513.e13.CrossRef Liu X, et al. Acetate production from glucose and coupling to mitochondrial metabolism in mammals. Cell. 2018;175(2):502-513.e13.CrossRef
28.
go back to reference Bose S, Ramesh V, Locasale JW. Acetate metabolism in physiology, cancer, and beyond. Trends Cell Biol. 2019;29(9):695–703.CrossRef Bose S, Ramesh V, Locasale JW. Acetate metabolism in physiology, cancer, and beyond. Trends Cell Biol. 2019;29(9):695–703.CrossRef
29.
go back to reference Nieman KM, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17(11):1498–503.CrossRef Nieman KM, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17(11):1498–503.CrossRef
30.
go back to reference Costello LC, Franklin RB. ‘Why do tumour cells glycolyse?’: from glycolysis through citrate to lipogenesis. Mol Cell Biochem. 2005;280(1):1–8.CrossRef Costello LC, Franklin RB. ‘Why do tumour cells glycolyse?’: from glycolysis through citrate to lipogenesis. Mol Cell Biochem. 2005;280(1):1–8.CrossRef
31.
go back to reference Moreadith RA, Lehninger AL. The pathways of glutamate and glutamine oxidation by tumor cell mitochondria Role of mitochondrial NAD (P)+-dependent malic enzyme. J Biol Chem. 1984;259(10):6215–21.CrossRef Moreadith RA, Lehninger AL. The pathways of glutamate and glutamine oxidation by tumor cell mitochondria Role of mitochondrial NAD (P)+-dependent malic enzyme. J Biol Chem. 1984;259(10):6215–21.CrossRef
32.
go back to reference Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. 2010;35(8):427–33.CrossRef Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. 2010;35(8):427–33.CrossRef
33.
go back to reference Freidman N, et al. Amino acid transporters and exchangers from the SLC1A family: structure, mechanism and roles in physiology and cancer. Neurochem Res. 2020;45(6):1268–86.CrossRef Freidman N, et al. Amino acid transporters and exchangers from the SLC1A family: structure, mechanism and roles in physiology and cancer. Neurochem Res. 2020;45(6):1268–86.CrossRef
34.
go back to reference Gao P, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458(7239):762–5.CrossRef Gao P, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458(7239):762–5.CrossRef
35.
go back to reference Wise DR, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci. 2008;105(48):18782–7.CrossRef Wise DR, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci. 2008;105(48):18782–7.CrossRef
36.
go back to reference Nicklin P, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 2009;136(3):521–34.CrossRef Nicklin P, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 2009;136(3):521–34.CrossRef
37.
go back to reference Choi B-H, Coloff JLJC. The diverse functions of non-essential amino acids in cancer. Cancers. 2019;11(5):675.CrossRef Choi B-H, Coloff JLJC. The diverse functions of non-essential amino acids in cancer. Cancers. 2019;11(5):675.CrossRef
38.
go back to reference Ren P, et al. ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation. J Pathol. 2015;235(1):90–100.CrossRef Ren P, et al. ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation. J Pathol. 2015;235(1):90–100.CrossRef
39.
go back to reference Perillo B, et al. ROS in cancer therapy: the bright side of the moon. Exp Mol Med. 2020;52(2):192–203.CrossRef Perillo B, et al. ROS in cancer therapy: the bright side of the moon. Exp Mol Med. 2020;52(2):192–203.CrossRef
40.
go back to reference Saito Y, Soga T. Amino acid transporters as emerging therapeutic targets in cancer. Cancer Sci. 2021;112(8):2958–65.CrossRef Saito Y, Soga T. Amino acid transporters as emerging therapeutic targets in cancer. Cancer Sci. 2021;112(8):2958–65.CrossRef
41.
go back to reference Tang B, et al. SLC7A5 promotes colorectal cancer progression by regulating cell cycle and migration. In: Research Square. 2021. Tang B, et al. SLC7A5 promotes colorectal cancer progression by regulating cell cycle and migration. In: Research Square. 2021.
42.
go back to reference Yoo H-C, Han J-MJC. Amino acid metabolism in cancer drug resistance. Cells. 2022;11(1):140.CrossRef Yoo H-C, Han J-MJC. Amino acid metabolism in cancer drug resistance. Cells. 2022;11(1):140.CrossRef
43.
go back to reference Ning Y-X, et al. Let-7d increases ovarian cancer cell sensitivity to a genistein analog by targeting c-Myc. Oncotarget. 2017;8(43):74836.CrossRef Ning Y-X, et al. Let-7d increases ovarian cancer cell sensitivity to a genistein analog by targeting c-Myc. Oncotarget. 2017;8(43):74836.CrossRef
44.
go back to reference Zhou M, et al. Rapid mass spectrometric metabolic profiling of blood sera detects ovarian cancer with high accuracy. Cancer Epidemiol Biomark Prev. 2010;19(9):2262–71.CrossRef Zhou M, et al. Rapid mass spectrometric metabolic profiling of blood sera detects ovarian cancer with high accuracy. Cancer Epidemiol Biomark Prev. 2010;19(9):2262–71.CrossRef
45.
go back to reference Gong W, Chen Y, Zhang Y. Prognostic and clinical significance of Solute Carrier Family 7 Member 1 in ovarian cancer. Transl Cancer Res. 2021;10(2):602.CrossRef Gong W, Chen Y, Zhang Y. Prognostic and clinical significance of Solute Carrier Family 7 Member 1 in ovarian cancer. Transl Cancer Res. 2021;10(2):602.CrossRef
46.
go back to reference Neurauter G, et al. Chronic immune stimulation correlates with reduced phenylalanine turnover. Curr Drug Metab. 2008;9(7):622–7.CrossRef Neurauter G, et al. Chronic immune stimulation correlates with reduced phenylalanine turnover. Curr Drug Metab. 2008;9(7):622–7.CrossRef
47.
go back to reference Strasser B, et al. Mechanisms of inflammation-associated depression: immune influences on tryptophan and phenylalanine metabolisms. Curr Top Behav Neurosci. 2017;31:95–115.CrossRef Strasser B, et al. Mechanisms of inflammation-associated depression: immune influences on tryptophan and phenylalanine metabolisms. Curr Top Behav Neurosci. 2017;31:95–115.CrossRef
48.
go back to reference Sikalidis AK. Amino acids and immune response: a role for cysteine, glutamine, phenylalanine, tryptophan and arginine in T-cell function and cancer? Pathol Oncol Res. 2015;21(1):9–17.CrossRef Sikalidis AK. Amino acids and immune response: a role for cysteine, glutamine, phenylalanine, tryptophan and arginine in T-cell function and cancer? Pathol Oncol Res. 2015;21(1):9–17.CrossRef
49.
go back to reference Garcia E, et al. Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microflow NMR probe. J Proteome Res. 2011;10(4):1765–71.CrossRef Garcia E, et al. Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microflow NMR probe. J Proteome Res. 2011;10(4):1765–71.CrossRef
50.
go back to reference Mierziak J, Burgberger M, Wojtasik WJB. 3-hydroxybutyrate as a metabolite and a signal molecule regulating processes of living organisms. Biomolecules. 2021;11(3):402.CrossRef Mierziak J, Burgberger M, Wojtasik WJB. 3-hydroxybutyrate as a metabolite and a signal molecule regulating processes of living organisms. Biomolecules. 2021;11(3):402.CrossRef
51.
go back to reference Jin L, Zhou Y. Crucial role of the pentose phosphate pathway in malignant tumors. Oncol Lett. 2019;17(5):4213–21. Jin L, Zhou Y. Crucial role of the pentose phosphate pathway in malignant tumors. Oncol Lett. 2019;17(5):4213–21.
52.
go back to reference MacPherson RE, et al. Sarcolipin knockout mice fed a high-fat diet exhibit altered indices of adipose tissue inflammation and remodeling. Obesity. 2016;24(7):1499–505.CrossRef MacPherson RE, et al. Sarcolipin knockout mice fed a high-fat diet exhibit altered indices of adipose tissue inflammation and remodeling. Obesity. 2016;24(7):1499–505.CrossRef
53.
go back to reference Pape KA, et al. Inflammatory cytokines enhance the in vivo clonal expansion and differentiation of antigen-activated CD4+ T cells. J Immunol. 1997;159(2):591–8. Pape KA, et al. Inflammatory cytokines enhance the in vivo clonal expansion and differentiation of antigen-activated CD4+ T cells. J Immunol. 1997;159(2):591–8.
54.
go back to reference Mak TW, et al. Glutathione primes T cell metabolism for inflammation. Immunity. 2017;46(4):675–89.CrossRef Mak TW, et al. Glutathione primes T cell metabolism for inflammation. Immunity. 2017;46(4):675–89.CrossRef
55.
go back to reference Wheeler ML, DeFranco AL. Prolonged production of reactive oxygen species in response to B cell receptor stimulation promotes B cell activation and proliferation. J Immunol. 2012;189(9):4405–16.CrossRef Wheeler ML, DeFranco AL. Prolonged production of reactive oxygen species in response to B cell receptor stimulation promotes B cell activation and proliferation. J Immunol. 2012;189(9):4405–16.CrossRef
57.
go back to reference Sheng CK, Wright DM, Apostolopoulos V. Inflammatory mediators hold the key to dendritic cell suppression and tumor progression. Curr Med Chem. 2011;18(36):5507–18.CrossRef Sheng CK, Wright DM, Apostolopoulos V. Inflammatory mediators hold the key to dendritic cell suppression and tumor progression. Curr Med Chem. 2011;18(36):5507–18.CrossRef
60.
go back to reference Lim JP, et al. Monocyte chemoattractant protein-1: a proinflammatory cytokine elevated in sarcopenic obesity. Clin Interv Aging. 2015;10:605. Lim JP, et al. Monocyte chemoattractant protein-1: a proinflammatory cytokine elevated in sarcopenic obesity. Clin Interv Aging. 2015;10:605.
61.
go back to reference Fielding R, et al. L-carnitine supplementation in recovery after exercise. Nutrients. 2018;10(3):349.CrossRef Fielding R, et al. L-carnitine supplementation in recovery after exercise. Nutrients. 2018;10(3):349.CrossRef
62.
go back to reference Shao H, et al. Carnitine palmitoyltransferase 1A functions to repress FoxO transcription factors to allow cell cycle progression in ovarian cancer. Oncotarget. 2016;7(4):3832.CrossRef Shao H, et al. Carnitine palmitoyltransferase 1A functions to repress FoxO transcription factors to allow cell cycle progression in ovarian cancer. Oncotarget. 2016;7(4):3832.CrossRef
63.
go back to reference Cheon D-J, et al. A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancercollagen-remodeling gene signature predicts poor survival. Clin Cancer Res. 2014;20(3):711–23.CrossRef Cheon D-J, et al. A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancercollagen-remodeling gene signature predicts poor survival. Clin Cancer Res. 2014;20(3):711–23.CrossRef
64.
go back to reference von Strandmann EP, et al. Tumor–host cell interactions in ovarian cancer: pathways to therapy failure. Trends in cancer. 2017;3(2):137–48.CrossRef von Strandmann EP, et al. Tumor–host cell interactions in ovarian cancer: pathways to therapy failure. Trends in cancer. 2017;3(2):137–48.CrossRef
65.
go back to reference Marchan R, et al. Glycerol-3-phosphate acyltransferase 1 promotes tumor cell migration and poor survival in ovarian carcinomaGPAM mediates tumor cell migration. Can Res. 2017;77(17):4589–601.CrossRef Marchan R, et al. Glycerol-3-phosphate acyltransferase 1 promotes tumor cell migration and poor survival in ovarian carcinomaGPAM mediates tumor cell migration. Can Res. 2017;77(17):4589–601.CrossRef
66.
go back to reference Schug ZT, et al. Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. Cancer Cell. 2015;27(1):57–71.CrossRef Schug ZT, et al. Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. Cancer Cell. 2015;27(1):57–71.CrossRef
67.
go back to reference Cipolletta D, et al. Appearance and disappearance of the mRNA signature characteristic of Treg cells in visceral adipose tissue: age, diet, and PPARγ effects. Proc Natl Acad Sci. 2015;112(2):482–7.CrossRef Cipolletta D, et al. Appearance and disappearance of the mRNA signature characteristic of Treg cells in visceral adipose tissue: age, diet, and PPARγ effects. Proc Natl Acad Sci. 2015;112(2):482–7.CrossRef
68.
go back to reference Liu M, et al. Circulating tregs accumulate in omental tumors and acquire adipose-resident features. Cancer Immunol Res. 2022;10(5):641–55.CrossRef Liu M, et al. Circulating tregs accumulate in omental tumors and acquire adipose-resident features. Cancer Immunol Res. 2022;10(5):641–55.CrossRef
69.
go back to reference Geyeregger R, et al. Polyunsaturated fatty acids interfere with formation of the immunological synapse. J Leukoc Biol. 2005;77(5):680–8.CrossRef Geyeregger R, et al. Polyunsaturated fatty acids interfere with formation of the immunological synapse. J Leukoc Biol. 2005;77(5):680–8.CrossRef
70.
go back to reference Li P, et al. Plasma omega-3 polyunsaturated fatty acids and recurrence of endometrial cancer. BMC Cancer. 2020;20(1):1–11.CrossRef Li P, et al. Plasma omega-3 polyunsaturated fatty acids and recurrence of endometrial cancer. BMC Cancer. 2020;20(1):1–11.CrossRef
71.
go back to reference Mika A, et al. Preferential uptake of polyunsaturated fatty acids by colorectal cancer cells. Sci Rep. 2020;10(1):1–8.CrossRef Mika A, et al. Preferential uptake of polyunsaturated fatty acids by colorectal cancer cells. Sci Rep. 2020;10(1):1–8.CrossRef
72.
go back to reference Meyer KA, et al. Adipocytes promote pancreatic cancer cell proliferation via glutamine transfer. Biochem Biophys Rep. 2016;7:144–9. Meyer KA, et al. Adipocytes promote pancreatic cancer cell proliferation via glutamine transfer. Biochem Biophys Rep. 2016;7:144–9.
73.
go back to reference Krutilina RI, et al. HIF-dependent CKB expression promotes breast cancer metastasis, whereas cyclocreatine therapy impairs cellular invasion and improves chemotherapy efficacy. Cancers. 2021;14(1):27.CrossRef Krutilina RI, et al. HIF-dependent CKB expression promotes breast cancer metastasis, whereas cyclocreatine therapy impairs cellular invasion and improves chemotherapy efficacy. Cancers. 2021;14(1):27.CrossRef
74.
go back to reference Li X-H, et al. Knockdown of creatine kinase B inhibits ovarian cancer progression by decreasing glycolysis. Int J Biochem Cell Biol. 2013;45(5):979–86.CrossRef Li X-H, et al. Knockdown of creatine kinase B inhibits ovarian cancer progression by decreasing glycolysis. Int J Biochem Cell Biol. 2013;45(5):979–86.CrossRef
75.
go back to reference Mooney SM, et al. Creatine kinase brain overexpression protects colorectal cells from various metabolic and non-metabolic stresses. J Cell Biochem. 2011;112(4):1066–75.CrossRef Mooney SM, et al. Creatine kinase brain overexpression protects colorectal cells from various metabolic and non-metabolic stresses. J Cell Biochem. 2011;112(4):1066–75.CrossRef
76.
go back to reference Fenouille N, et al. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Nat Med. 2017;23(3):301–13.CrossRef Fenouille N, et al. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Nat Med. 2017;23(3):301–13.CrossRef
77.
go back to reference Kurmi K, et al. Tyrosine phosphorylation of mitochondrial creatine kinase 1 enhances a druggable tumor energy shuttle pathway. Cell Metab. 2018;28(6):833-847.e8.CrossRef Kurmi K, et al. Tyrosine phosphorylation of mitochondrial creatine kinase 1 enhances a druggable tumor energy shuttle pathway. Cell Metab. 2018;28(6):833-847.e8.CrossRef
78.
go back to reference Papalazarou V, et al. The creatine–phosphagen system is mechanoresponsive in pancreatic adenocarcinoma and fuels invasion and metastasis. Nat Metab. 2020;2(1):62–80.CrossRef Papalazarou V, et al. The creatine–phosphagen system is mechanoresponsive in pancreatic adenocarcinoma and fuels invasion and metastasis. Nat Metab. 2020;2(1):62–80.CrossRef
79.
go back to reference Iwagoi Y, et al. Omental metastasis as a predictive risk factor for unfavorable prognosis in patients with stage III–IV epithelial ovarian cancer. Int J Clin Oncol. 2021;26(5):995–1004.CrossRef Iwagoi Y, et al. Omental metastasis as a predictive risk factor for unfavorable prognosis in patients with stage III–IV epithelial ovarian cancer. Int J Clin Oncol. 2021;26(5):995–1004.CrossRef
80.
go back to reference Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol. 2007;18(5):945–9.CrossRef Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol. 2007;18(5):945–9.CrossRef
81.
go back to reference Menendez JA. Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: molecular mechanisms and therapeutic perspectives. Biochim Biophys Acta Mol Cell Biol Lipids. 2010;1801(3):381–91.CrossRef Menendez JA. Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: molecular mechanisms and therapeutic perspectives. Biochim Biophys Acta Mol Cell Biol Lipids. 2010;1801(3):381–91.CrossRef
82.
go back to reference Luo X, et al. Emerging roles of lipid metabolism in cancer metastasis. Mol Cancer. 2017;16(1):1–10.CrossRef Luo X, et al. Emerging roles of lipid metabolism in cancer metastasis. Mol Cancer. 2017;16(1):1–10.CrossRef
83.
go back to reference Meiser J, et al. Increased formate overflow is a hallmark of oxidative cancer. Nat Commun. 2018;9(1):1–12.CrossRef Meiser J, et al. Increased formate overflow is a hallmark of oxidative cancer. Nat Commun. 2018;9(1):1–12.CrossRef
Metadata
Title
Acidic ascites inhibits ovarian cancer cell proliferation and correlates with the metabolomic, lipidomic and inflammatory phenotype of human patients
Authors
Qianlu Yang
Gyuntae Bae
Giorgi Nadiradze
Arianna Castagna
Georgy Berezhnoy
Laimdota Zizmare
Aditi Kulkarni
Yogesh Singh
Frank J. Weinreich
Stefan Kommoss
Marc A. Reymond
Christoph Trautwein
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-022-03763-3

Other articles of this Issue 1/2022

Journal of Translational Medicine 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.